161 related articles for article (PubMed ID: 38139333)
21. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
[TBL] [Abstract][Full Text] [Related]
22. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
24. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
25. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.
Chiu SJ; Chao JI; Lee YJ; Hsu TS
Toxicol Lett; 2008 Jun; 179(2):63-70. PubMed ID: 18499365
[TBL] [Abstract][Full Text] [Related]
26. Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells.
Poel D; Boyd LNC; Beekhof R; Schelfhorst T; Pham TV; Piersma SR; Knol JC; Jimenez CR; Verheul HMW; Buffart TE
Cells; 2019 Sep; 8(9):. PubMed ID: 31546954
[TBL] [Abstract][Full Text] [Related]
27. Supramolecular Chemotherapy: Carboxylated Pillar[6]arene for Decreasing Cytotoxicity of Oxaliplatin to Normal Cells and Improving Its Anticancer Bioactivity Against Colorectal Cancer.
Hao Q; Chen Y; Huang Z; Xu JF; Sun Z; Zhang X
ACS Appl Mater Interfaces; 2018 Feb; 10(6):5365-5372. PubMed ID: 29355009
[TBL] [Abstract][Full Text] [Related]
28. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
[TBL] [Abstract][Full Text] [Related]
29. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
[TBL] [Abstract][Full Text] [Related]
30. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
[TBL] [Abstract][Full Text] [Related]
31. Hwang-Heuk-San induces apoptosis in HCT116 human colorectal cancer cells through the ROS-mediated activation of caspases and the inactivation of the PI3K/Akt signaling pathway.
Lee MH; Hong SH; Park C; Kim GY; Leem SH; Choi SH; Keum YS; Hyun JW; Kwon TK; Hong SH; Choi YH
Oncol Rep; 2016 Jul; 36(1):205-14. PubMed ID: 27221553
[TBL] [Abstract][Full Text] [Related]
32. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
[TBL] [Abstract][Full Text] [Related]
33. The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells.
Allen WL; McLean EG; Boyer J; McCulla A; Wilson PM; Coyle V; Longley DB; Casero RA; Johnston PG
Mol Cancer Ther; 2007 Jan; 6(1):128-37. PubMed ID: 17237273
[TBL] [Abstract][Full Text] [Related]
34. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
Park J; Lee GE; An HJ; Lee CJ; Cho ES; Kang HC; Lee JY; Lee HS; Choi JS; Kim DJ; Choi JS; Cho YY
Arch Pharm Res; 2021 Dec; 44(12):1091-1108. PubMed ID: 34750753
[TBL] [Abstract][Full Text] [Related]
35. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.
Howells LM; Sale S; Sriramareddy SN; Irving GR; Jones DJ; Ottley CJ; Pearson DG; Mann CD; Manson MM; Berry DP; Gescher A; Steward WP; Brown K
Int J Cancer; 2011 Jul; 129(2):476-86. PubMed ID: 20839263
[TBL] [Abstract][Full Text] [Related]
36. Oxali(IV)Fluors: Fluorescence Responsive Oxaliplatin(IV) Complexes Identify a Hypoxia-Dependent Reduction in Cancer Cells.
Boulet MHC; Bolland HR; Hammond EM; Sedgwick AC
J Am Chem Soc; 2023 Jun; 145(24):12998-13002. PubMed ID: 37283248
[TBL] [Abstract][Full Text] [Related]
37. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
Huang C; Zhou T; Ma L; Zhao S
Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.
Yang C; Zhou Q; Li M; Tong X; Sun J; Qing Y; Sun L; Yang X; Hu X; Jiang J; Yan X; He L; Wan C
Sci Rep; 2016 Sep; 6():33078. PubMed ID: 27609465
[TBL] [Abstract][Full Text] [Related]
39. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.
Bose D; Zimmerman LJ; Pierobon M; Petricoin E; Tozzi F; Parikh A; Fan F; Dallas N; Xia L; Gaur P; Samuel S; Liebler DC; Ellis LM
Br J Cancer; 2011 Nov; 105(11):1759-67. PubMed ID: 22045189
[TBL] [Abstract][Full Text] [Related]
40. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
